Citations 1
A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer.
Konecny, Gottfried E. , Hendrickson, Andrea E. Wahner , Jatoi, Aminah , Burton, Jill K., Paroly, Jill, Dowdy, Sean C. , Slamon, Dennis J. , Glaspy, John A.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 5557-5557
